Study cohort included 20 non-neurogenic, unresponsive to treatment UAB patients with post-void residual (PVR) of 150 ml or more. Research team performed a biopsy of Quadriceps femoris muscle and sent 150+ mg of tissue to the processing lab where cells were isolated from the muscle specimen. Cell culture was performed, tested for quality, and shipped back to the site. Each subject received 30 intradetrusor injections of 0.5 mL for a total of 15 mL using a flexible cystoscope under local topical anesthesia.
According to the presenter, there were no serious adverse events related to muscle harvesting, AMDC, and injections. Data indicate improvement in UAB symptoms at the assessment time points (Table 1).
Table 1
Interim analysis of AMDC injections shows improvement trend in overall bladder function and safety. Future multi-center controlled study is needed to further investigate effects of a novel therapy for patients with UAB.
Presented by: Ananias C. Diokno, MD; Oakland University William Beaumont School of Medicine
Written by: Hanna Stambakio, BS, Clinical Research Coordinator, Division of Urology, University of Pennsylvania @AStambakio at the American Urological Association's 2019 Annual Meeting (AUA 2019), May 3 – 6, 2019 in Chicago, Illinois